Concourse Financial Group Securities, Inc. Axcella Health Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share
Q2 2023 Aug 10, 2023	BUY	$0.22 - $0.46 $0 - $0
Q1 2023 May 15, 2023	BUY	$0.31 - $0.77 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$0.16 - $1.1 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$1.62 - $2.73 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$1.41 - $2.77 $0 - $0
Q1 2022 May 09, 2022	BUY	$1.58 - $2.82 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$2.06 - $3.61 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$2.98 - $4.31 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$3.08 - $5.13 $0 - $0
Q1 2021 May 13, 2021	BUY	$4.55 - $6.72 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$4.24 - $5.97 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$4.12 - $5.91 $0 - $0
Q2 2020 Aug 13, 2020	BUY	$2.94 - $7.7 $0 - $0
Q1 2020 May 13, 2020	BUY	$2.25 - $5.24 $0 - $0
Q4 2019 Feb 14, 2020	BUY	$3.08 - $5.9 $0 - $0
Q3 2019 Nov 13, 2019	BUY	$5.25 - $9.26 $0 - $0
Q2 2019 Aug 13, 2019	BUY	$8.51 - $14.95 $0 - $0

Others Institutions Holding AXLA

# of Institutions

Shares Held

61.6K

Call Options Held

Put Options Held

View Full List

About Axcella Health Inc.

Ticker AXLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,500,896
Description
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrenc...

More about AXLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account